Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Pharmacogenomics J. 2010 Mar 2;11(2):146–154. doi: 10.1038/tpj.2010.12

Table 3.

Demographics by remission status at 6-months

Remitted N = 85 Nonremitted N = 125 Test value p value
BDNF (% Met/*) 47.1% (40/85) 33.6% (42/125) χ2 = 3.85 0.0497
Age 69.6 (7.8) 69.4 (7.1) t = 0.22 0.8242
Age of onset 47.2 (19.0) 43.3 (21.4) t = 1.32 0.1898
Sex (% Female) 65.9% (56/85) 60.8% (76/125) χ2 = 0.41 0.5244
Education 13.8 (2.7) 13.9 (2.7) t = 0.19 0.8524
MMSE 28.1 (2.3) 28.2 (2.2) t = 0.17 0.8664
MADRS, baseline 27.4 (8.6) 26.4 (7.5) t = 0.89 0.3733
CIRS 4.1 (3.4) 4.3 (2.9) t = 0.39 0.6994
IADL score 2.9 (4.3) 3.8 (4.7) t = 1.52 0.1289
Subjective SS (Unadjusted) 24.0 (3.4) 22.1 (4.0) t = 2.09 0.0380
Subjective SS (Log) 3.2 (0.2) 3.1 (0.2) t = 2.35 0.0198
WML volume 6.1 (11.6) 6.7 (9.9) t = 0.36 0.7166

All comparisons of continuous variables used pooled, two-tailed t-tests with 208 df, except for analyses of subjective social support which used a Satterthwaite t-test with 198 df due to unequal variances. Age and education variables presented in years, white matter hyperintense lesion (WML) volume presented in milliliters.